Panobinostat (LBH589)

目录号：S1030 别名： NVP-LBH589

Molecular Weight(MW): 349.43

Panobinostat (LBH589)是一种新型的，广谱HDAC抑制剂，无细胞试验中IC50为5 nM。Phase 3。

规格

价格

库存

购买数量

10mg	RMB 731.86	现货
50mg	RMB 2189.52	现货
200mg	RMB 5485.18	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献216篇：

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2019, 36(5):528-544

PubMed: 31631026 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):782-797

PubMed: 31085178 ( click the link to review the publication )

Nat Immunol, 2019, 20(7):835-851

PubMed: 31160797 ( click the link to review the publication )

Nat Med, 2018, 24(11):1752-1761

PubMed: 30349086 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Nat Genet, 2018, 50(10):1442-1451

PubMed: 30224647 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cell, 2014, 159(5):1110-25

PubMed: 25416949 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-019-04021-y

PubMed: 31894347 ( click the link to review the publication )

Cell Res, 2019, 29(4):286-304

PubMed: 30631154 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3319

PubMed: 31346162 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0525-6

PubMed: 31358854 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(26):12986-12995

PubMed: 31182587 ( click the link to review the publication )

Neuro Oncol, 2019, 10.1093/neuonc/noz215

PubMed: 31711240 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(2):230-243

PubMed: 30563830 ( click the link to review the publication )
Cancer Res, 2019, 79(11):2947-2961

PubMed: 30987999 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Clin Infect Dis, 2019, 10.1093/cid/ciz108

PubMed: 30753360 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cell Rep, 2019, 29(9):2783-2795

PubMed: 31775045 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):185

PubMed: 31053152 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

PLoS Pathog, 2019, 15(8):e1007991

PubMed: 31425551 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):134

PubMed: 31801577 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(1):185-195

PubMed: 30301863 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2019, 1865(6):1666-1676

PubMed: 30954557 ( click the link to review the publication )

J Biomed Nanotechnol, 2019, 15(5):979-992

PubMed: 30890229 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Biomolecules, 2019, 9(5)

PubMed: 31083537 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18970-18984

PubMed: 30916359 ( click the link to review the publication )
Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )

J Virol, 2019, 93(24)

PubMed: 31578289 ( click the link to review the publication )

Antimicrob Agents Chemother, 2019, 63(2)

PubMed: 30455231 ( click the link to review the publication )

Epigenetics Chromatin, 2019, 12(1):18

PubMed: 30871586 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(12)

PubMed: 31234549 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Apoptosis, 2019, 24(1-2):184-197

PubMed: 30498998 ( click the link to review the publication )

Mol Carcinog, 2019, 58(12):2230-2240

PubMed: 31478563 ( click the link to review the publication )

Mol Carcinog, 2019, 58(2):234-246

PubMed: 30303565 ( click the link to review the publication )

Virus Res, 2019, 269:197631

PubMed: 31136823 ( click the link to review the publication )

Mol Genet Genomic Med, 2019, 7(5):e613

PubMed: 30891950 ( click the link to review the publication )

Childs Nerv Syst, 2019, 35(5):823-831

PubMed: 30815722 ( click the link to review the publication )

J Nanobiotechnology, 2019, 17(1):69

PubMed: 31113488 ( click the link to review the publication )

J Virus Erad, 2019, 5(3):133-137

PubMed: 31700655 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4866

PubMed: 30451831 ( click the link to review the publication )

Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(1):120-129.

PubMed: 29066507 ( click the link to review the publication )

Cancer Res, 2018, 78(5):1155-1168

PubMed: 29259009 ( click the link to review the publication )

Cancer Res, 2018, 78(14):4007-4021

PubMed: 29760046 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Oncogene, 2018, 37(6):722-731

PubMed: 29059175 ( click the link to review the publication )

Cancer Lett, 2018, 417:152-160

PubMed: 29306016 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )
EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1705-1716

PubMed: 29748211 ( click the link to review the publication )

Cell Oncol (Dordr), 2018, 41(2):201-212

PubMed: 29260509 ( click the link to review the publication )

J Immunol, 2018, 201(3):1086-1096

PubMed: 29914885 ( click the link to review the publication )

J Virol, 2018, 92(13)

PubMed: 29643247 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9472

PubMed: 29930256 ( click the link to review the publication )

Biomed Pharmacother, 2018, 100:509-520

PubMed: 29494986 ( click the link to review the publication )

J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

J Ethnopharmacol, 2018, 211:267-277

PubMed: 28970153 ( click the link to review the publication )

Exp Cell Res, 2018, 363(2):196-207

PubMed: 29317217 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207915

PubMed: 30481203 ( click the link to review the publication )

PLoS One, 2018, 13(12):e0208147

PubMed: 30592723 ( click the link to review the publication )

Dis Markers, 2018, 2018:3810108

PubMed: 30647797 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(1):61-74

PubMed: 29049036 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36530-36541

PubMed: 30559935 ( click the link to review the publication )

Oncotarget, 2018, 9(5):6450-6462

PubMed: 29464084 ( click the link to review the publication )

F1000Res, 2018, 7:1906

PubMed: 30881689 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28586-28598

PubMed: 29983882 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2018, 100(1):174-187

PubMed: 29107335 ( click the link to review the publication )
Nat Commun, 2017, 8(1):728

PubMed: 28959017 ( click the link to review the publication )

Cancer Res, 2017, 77(11):3027-3039

PubMed: 28363998 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

Plant Physiol, 2017, 175(4):1760-1773

PubMed: 29018096 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Arch Toxicol, 2017, 91(1):365-391

PubMed: 27015953 ( click the link to review the publication )

Arch Toxicol, 2017, 91(2):839-864

PubMed: 27188386 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Br J Haematol, 2017, 178(5):728-738

PubMed: 28480959 ( click the link to review the publication )

Epigenetics, 2017, 12(2):105-112

PubMed: 27935420 ( click the link to review the publication )

Int J Nanomedicine, 2017, 12:1385-1399

PubMed: 28260886 ( click the link to review the publication )

J Biol Chem, 2017, 292(9):3683-3691

PubMed: 28087699 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )

Exp Cell Res, 2017, 350(1):218-225

PubMed: 27914787 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2017, 7(1):42-50

PubMed: 28107750 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169485

PubMed: 28052119 ( click the link to review the publication )

Horm Cancer, 2017, 8(4):257-267

PubMed: 28516379 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Blood Adv, 2017, 1(19):1575-1583

PubMed: 29296798 ( click the link to review the publication )

Genom Data, 2017, 12:14-16

PubMed: 28239551 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3908-3921

PubMed: 29423093 ( click the link to review the publication )
Oncotarget, 2017, 8(18):30019-30029

PubMed: 28415789 ( click the link to review the publication )

Oncotarget, 2017, 8(34):56747-56757

PubMed: 28915627 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )

Oncotarget, 2017, 8(55):94569-94579

PubMed: 29212250 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:127-148

PubMed: 27761818 ( click the link to review the publication )

Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(3):1159-1176

PubMed: 28180300 ( click the link to review the publication )

EMBO Mol Med, 2016, 8(2):117-38

PubMed: 26681773 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(10):2534-44

PubMed: 26733615 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Oncogene, 2016, 35(46):6026-6037

PubMed: 27157610 ( click the link to review the publication )

Mol Oncol, 2016, 10(5):735-750

PubMed: 26775640 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2016, 3:16003

PubMed: 27626039 ( click the link to review the publication )

J Org Chem, 2016, 81(22):11324-11334

PubMed: 27768313 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )

J Biol Chem, 2016, 291(16):8745-55

PubMed: 26912657 ( click the link to review the publication )

Biomed Pharmacother, 2016, 84:1393-1405

PubMed: 27802904 ( click the link to review the publication )

Retrovirology, 2016, 13(1):36

PubMed: 27206407 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Am J Transl Res, 2016, 8(9):3893-3902

PubMed: 27725868 ( click the link to review the publication )

PLoS One, 2016, 11(2):e0148912

PubMed: 26859414 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(11):2644-52

PubMed: 26980288 ( click the link to review the publication )

JCI Insight, 2016, 1(5):e85061

PubMed: 27699258 ( click the link to review the publication )
Ann Rheum Dis, 2015, 10.1136/annrheumdis-2014-206258

PubMed: 25589513 ( click the link to review the publication )

Biomaterials, 2015, 73:110-9

PubMed: 26406451 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: 25490700 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Arch Toxicol, 2015, 89(9):1599-618

PubMed: 26272509 ( click the link to review the publication )

Mol Oncol, 2015, 9(7):1447-1457

PubMed: 25957812 ( click the link to review the publication )

Mol Pharm, 2015, 12(7):2469-76

PubMed: 26030093 ( click the link to review the publication )

Sci Rep, 2015, 5:16445

PubMed: 26563568 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2015, 309(12):L1410-9

PubMed: 26498249 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(49):29478-92

PubMed: 26491017 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074.jbc.M114.624361

PubMed: 25737447 ( click the link to review the publication )

J Biol Chem, 2015, 290(49):29478-92

PubMed: 26491017 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(12):1784-93

PubMed: 26529495 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2015, 5(3):117-26

PubMed: 26199860 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0126566

PubMed: 26176219 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134426

PubMed: 26247786 ( click the link to review the publication )

Pediatr Blood Cancer, 2015, 62(1):52-9

PubMed: 25308916 ( click the link to review the publication )

Pediatr Blood Cancer, 2015, 62(1):52-9

PubMed: 25308916 ( click the link to review the publication )

Exp Hematol, 2015, 43(6):448-61

PubMed: 25704054 ( click the link to review the publication )

Oncotarget, 2015, 6(19):17698-712

PubMed: 25989842 ( click the link to review the publication )

Western University, 2015, Western University

PubMed: ( click the link to review the publication )
Oncotarget, 2015, 6(25):21507-21

PubMed: 26087189 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2088-100

PubMed: 25576920 ( click the link to review the publication )

Cancer Lett, 2014, 356(2 Pt B):656-68

PubMed: 25458954 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

PLoS Pathog, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Anal Chem, 2014, 86(10):4642-7

PubMed: 24559101 ( click the link to review the publication )

Br J Cancer, 2014, 111(2):281-91

PubMed: 24946002 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

J Immunol, 2014, 193(3):1333-43

PubMed: 24973453 ( click the link to review the publication )

Mol Carcinog, 2014, 53(9):722-35

PubMed: 23475695 ( click the link to review the publication )

BMC Cancer, 2014, 14:17

PubMed: 24418474 ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

PLoS One, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(3):649-54

PubMed: 25193706 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(12):6018-33

PubMed: 23625969 ( click the link to review the publication )

Leukemia, 2013, 27(6):1291-300

PubMed: 23411464 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Cancer Lett, 2013, 329(1):17-26

PubMed: 22995071 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(4):R58

PubMed: 23879992 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )
Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 162(4):559-62

PubMed: 23692150 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):429-33

PubMed: 23932191 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2013, 139(9):1507-14

PubMed: 23824064 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1325-34

PubMed: 23515752 ( click the link to review the publication )

PLoS One, 2013, 8(8):e74253

PubMed: 23991216 ( click the link to review the publication )

PLoS One, 2013, 8(11):e79106

PubMed: 24244429 ( click the link to review the publication )

PLoS One, 2013, 8(9):e76662

PubMed: 24098799 ( click the link to review the publication )

PLoS One, 2013, 8(7):e69992

PubMed: 23922886 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Theriogenology, 2013, 80(6):630-5

PubMed: 23866857 ( click the link to review the publication )

Protein Expr Purif, 2013, 92(1):119-127

PubMed: 24056254 ( click the link to review the publication )

Genet Mol Res, 2013, 12(4):5405-13

PubMed: 24301913 ( click the link to review the publication )

The University of Western Ontario, 2013, CHAE YOUNG HAN

PubMed: ( click the link to review the publication )

Obstet Gynecol Int, 2013, 2013:828165

PubMed: 24381593 ( click the link to review the publication )

Blood, 2012, 119(6):1450-8

PubMed: 22144178 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 131(3):777-89

PubMed: 21452019 ( click the link to review the publication )

J Neurooncol, 2012, 110(3):335-48

PubMed: 23054560 ( click the link to review the publication )

Acta Neuropathol, 2011, 122(5):637-50

PubMed: 21863243 ( click the link to review the publication )

PLoS One, 2011, 6(2):e17138

PubMed: 21359182 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Biochem Bioph Res Co, 2010, 391(4):1748-51

PubMed: 20043870 ( click the link to review the publication )

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述

Panobinostat (LBH589)是一种新型的，广谱HDAC抑制剂，无细胞试验中IC50为5 nM。Phase 3。

靶点

HDAC (MOLT-4 cells) ^[1]	HDAC (Reh cells) ^[1]
5 nM	20 nM

体外研究

LBH589诱导MOLT-4和Reh细胞凋亡，这种作用具有时间和剂量依赖性。而且，LBH589作用于MOLT-4细胞比作用于Reh细胞更有效。LBH589明显阻止MOLT-4 和Reh细胞的生长，处理48小时，具有剂量依赖性。与对照组细胞相比，用LBH589处理的细胞，在细胞周期的G2/M期的细胞数量增多2到3倍。LBH589与组蛋白H3K9和H4K8的乙酰化作用相关，LBH589也降低c-Myc的表达水平，具有剂量依赖性。LBH589也增强p21的表达水平。最低剂量的LBH589（10 nM）处理Reh细胞，最初增强c-Myc的表达水平，之后一直降低c-Myc的表达水平。此外，LBH589促进mRNA水平的促凋亡和DNA修复基因的大量增多。在GADD45G启动子作用下，LBH589诱导乙酰化的组蛋白H3 和H4水平的增多。^[1]此外, LBH589抑制非小细胞肺癌细胞系生长，如人类H1299,L55和A549，IC50分别为5,11和30 nM；间皮瘤细胞生长，如人类OK-6和 Ok-5，IC50分别为5和7 nM；及小细胞肺癌细胞系生长，如人类RG-1和LD-T，IC50分别为4和5 nM。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HT29	NXfTO\|luT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnP3NE0yOCEQvF2=	M4TZelAuPCCm		NH3HXGtqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NWHI[mdrOjZ5MEK3PFQ>
HepG2	NH3jPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX6wMVExKM7:TR?=	MUGwMVQh\A>?		NHXsUGRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M{XqO\|I3PzB{N{i0
HT29	MmThSpVv[3Srb36gRZN{[Xl?	NF;iNo02OMLibl2=	M3eyUlI1NTd{IHi=		NFHvRnRqdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB\|IHHmeIVzKDR6wrDoxsA>	NITQbFAzPjdyMke4OC=>
HepG2	MV\GeY5kfGmxbjDBd5NigQ>?	MXq1NOKhdk1?	NUH2NZI{OjRvN{KgbC=>		NV32ZmZmcW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMzDh[pRmeiB{NNMgbOKh	NVm1RZRrOjZ5MEK3PFQ>
HCC827	M2LqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEO5OoE2NzdwNT:xNEBvVQ>?	NVHCdYV2PzMEoHi=	MV\EUXNQ	NXz1eYh1\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK=	MYKyOlY4PTR6NB?=
A549	NIj4d3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXuxNE8yPS9{MDDuUS=>	M2jyVlczyqCq	M1vUXmROW09?	M{nvVIVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk	MWCyOlY4PTR6NB?=
NCI-H460	M4HUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUOxZZlGOTBxMkCvN\|Ahdk1?	MnvjO\|LDqGh?	NHHFco9FVVOR	MXLlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>?	NU\qbHc5OjZ4N{W0PFQ>
J89GFP	NEfpfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4XtTGROW00EoB?=	NULERmRFTUN3ME20PU45PSEEsTCxNk43PSCwTR?=	MnTZNlY2PjN3Nki=
THP89GFP	NYPz[nZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2L5dGROW00EoB?=	M3K2W2VEPTB;MUmuN\|QhyrFiNj60N{BvVQ>?	MUSyOlU3OzV4OB?=
SK-NEP-1	M3LPbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vsWFAvODIkgKOxNE4xKM7:TR?=	NWe3[294OjRiaB?=	MXfEUXNQyqB?	NEXYcnZKSzVyPUe2MlM1KG6P	NUjUTVRNOjZzN{[yNVk>
G401	NUGyVpVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWCwMlAy6oDVMUCuNEDPxE1?	MkTpNlQhcA>?	NHfBRphFVVORwrC=	M33QWWlEPTB;MUSzMlAzKG6P	NH2ySHIzPjF5NkKxPS=>
SK-NEP-1	NFXnXFNE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M3S2flUxKG6P	MW[x5qCUPCCm	NWDxOXNxTE2VT9Mg	MnPJdoVlfWOnczDj[YxtKHO3co\peoFtKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz	MVyyOlE4PjJzOR?=
G401	MWrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MmjmOVAhdk1?	NW\hNHdkOeLCk{Sg[C=>	NYDkWZo{TE2VT9Mg	NV7p[41TemWmdXPld{Bk\WyuIIP1dpZqfmGuIHnuJIEhfGmvZTDk[ZBmdmSnboSgcYFvdmW{	M17Kd\|I3OTd4MkG5
SK-NEP-1	MlSxRZBweHSxc3nzJGF{e2G7	MWe1NE8yODBibl2=	MXuyOEBp	MmHBSG1UV8Li	MmrDbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MlSyNlYyPzZ{MUm=
G401	MmqzRZBweHSxc3nzJGF{e2G7	M4HsbVUxNzFyMDDuUS=>	M{XkPFI1KGh?	Mo\YSG1UV8Li	MYfpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MorYNlYyPzZ{MUm=
SK-NEP-1	MUfGeY5kfGmxbjDBd5NigQ>?	NYjQOHdGPTBxMUCwJI5O	NHfKSGszPCCq	NFHnb2xFVVORwrC=	M3fOdZNpd3e\|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25?	NVT5Woo4OjZzN{[yNVk>
G401	MVfGeY5kfGmxbjDBd5NigQ>?	MVK1NE8yODBibl2=	MmfYNlQhcA>?	NW\SWZV1TE2VT9Mg	M1nhcpNpd3e\|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25?	NUPYfnNMOjZzN{[yNVk>
SK-NEP-1	MV3GeY5kfGmxbjDBd5NigQ>?	Ml\4OVAwOTByIH7N	NVzHUHhvOjRiaB?=	NGq0clBFVVORwrC=	MV7pcoR2[2W\|IHPlcIwh[3mlbHWg[Il{d3KmZYNCpC=>	MlrlNlYyPzZ{MUm=
G401	M2TzdmZ2dmO2aX;uJGF{e2G7	NFPaTHM2OC9zMECgcm0>	MlHmNlQhcA>?	M3HTeGROW00EoB?=	NF\GdmRqdmS3Y3XzJINmdGxiY4njcIUh\Gm\|b4Lk[ZLDqA>?	MlHxNlYyPzZ{MUm=
RPMI 8226	NV33UolMS2WubDDTeZJ3cX[jbDDBd5NigQ>?	NVzJdGN2Oi92L{[gcm0>	MoXlOFjjiImq		Mn;WbY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>?	M1\IWVI3ODByMkmy
OPM2	MWDD[YxtKFO3co\peoFtKEG\|c3H5	MnK5Nk81NzZibl2=	MnnDOFjjiImq		NYjqTmxScW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?=	M37YVFI3ODByMkmy
U266	MX\D[YxtKFO3co\peoFtKEG\|c3H5	NUHzd3pPOi92L{[gcm0>	MUO0PQKBkWh?		MX\pcoR2[2W\|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp	MmTRNlYxODB{OUK=
H929	MUHD[YxtKFO3co\peoFtKEG\|c3H5	M2rXeFIwPC94IH7N	NITxTYk1QOLCiXi=		M4\VNolv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh?	MojFNlYxODB{OUK=
RPMI 8226	NGrQfWJCeG:ydH;zbZMhSXO\|YYm=	MV605qCKdk1?	M4HOdlI1NzR6IHi=		NX7nU\|Z2cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	NVnMcWFzOjZyMECyPVI>
HCC827	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;5TVEyOCCwTR?=	NWX5OmhiPDhiaB?=	NHz1R5pFVVOR	NVzScllv\W6qYX7j[ZMh[2m\|cHzheIlvKHOnboPpeIl3cXS7wrC=	NH\Pe5kzPTl2NE[xOy=>
NCI-H23	M3f4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX[xNEBvVQ>?	MoroOFghcA>?	NYLHUXcyTE2VTx?=	MUTlcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>?	NVzybZhKOjV7NES2NVc>
AML3	M1zLeGZ2dmO2aX;uJGF{e2G7	M2TqNFAuOSEQvF2=	MoDVNlTDqGh?		M3u4cIlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NYfp[HRROjV4MUK5OFE>
ML-1	NF;yXmtHfW6ldHnvckBCe3OjeR?=	NIL0UZoxNTFizszN	MmLGNlTDqGh?		MlOxbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MWGyOVYyOjl2MR?=
RPMI-8226vr10	NHvjVVhHfW6ldHnvckBCe3OjeR?=	MmfaNE0yKM7:TR?=	NEe3[5kzPMLiaB?=		NXG1ZnFpcW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NYrBb2FDOjV4MUK5OFE>
ML-1	M3fVZ2Z2dmO2aX;uJGF{e2G7	Mn7yNUDPxE1?	NWmyVIhbOjUEoHi=		NVPjOFZwcW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB2LX\vcIQ>	M1v4NlI2PjF{OUSx
RPMI-8226vr10	Ml3ZSpVv[3Srb36gRZN{[Xl?	M4nENVEh\|ryP	M2e1VlI1yqCq		NH7aWHBqdmO{ZXHz[ZMh[2G\|cHHz[U0{KGGldHn2bZR6KDJwNT3mc4xl	MWCyOVYyOjl2MR?=
SK-N-BE (2)	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFjwfJczPOLCiXi=		NX7JPWI1UUN3ME2xNFQvOOLCidMx5qCKPy56IH7N	MXGyOVMxQDlzNh?=
SK-N-BE (2), PAN MK	M2PqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mn\oNlTjiImq		NGqwbnZKSzVyPUGwOE4x6oDLwsJihKk4Njhibl2=	M4LDclI2OzB6OUG2
SK-N-BE (2), MK PAN	NIDmcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUXKdml6OjUkgJno		M1O0OmlEPTB;M{iyMlDjiIoEsfMAjVQ{NjJibl2=	NGSzPHUzPTNyOEmxOi=>
SK-N-AS	NYe0Oll4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml;lNlTjiImq		NVHqPYhDUUN3ME2zO{4y6oDLwsJihKkzNjRibl2=	Mn;wNlU{ODh7MU[=
SK-N-DZ	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3HrNlI16oDLaB?=		MnPXTWM2OD1zNz6x5qCKyrIkgJmwMlQhdk1?	MXOyOVMxQDlzNh?=
Caki-1	NX3WT4h[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX:xNE8zPS93MDDuUS=>	M120VlQ5KGh?		NI\JNGJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK=	MYWyOVI4QTF7MR?=
ACHN	NHPldWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2m3Z\|ExNzJ3L{WwJI5O	NGS3dpY1QCCq		M4PoOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?=	NEfXVGIzPTJ5OUG5NS=>
769-P	NH\EUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDjb3QyOC9{NT:1NEBvVQ>?	MoSzOFghcA>?		NGnuOmtqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK=	MnflNlUzPzlzOUG=
786-O	Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2[wdlExNzJ3L{WwJI5O	NFvK[Yw1QCCq		MX7pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ?	MYWyOVI4QTF7MR?=
Caki-1	MnfMRZBweHSxc3nzJGF{e2G7	NYK2T4tLPTBibl2=	MljVOFghcA>?		MmnybY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ?	Mm\jNlUzPzlzOUG=
ACHN	NXHYW\|N3SXCxcITvd4l{KEG\|c3H5	NUnDZZlCPTBibl2=	NU\IdJUyPDhiaB?=		NX73fJlocW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK=	MlfZNlUzPzlzOUG=
769-P	MUTBdI9xfG:\|aYOgRZN{[Xl?	NHLqXY82OCCwTR?=	NGCxSYY1QCCq		MYXpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>?	NY\LZnhoOjV{N{mxPVE>
786-O	NGC2Ro9CeG:ydH;zbZMhSXO\|YYm=	MVK1NEBvVQ>?	M1nyN\|Q5KGh?		Ml3RbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ?	NVnBRWFVOjV{N{mxPVE>
Caki-1	NGjRTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M125clI2NzVyIH7N	M2TpRlQ5KGh?	NVPGUJBXTE2VTx?=	Ml;VbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?=	NUW2dlB1OjVzN{[zOVQ>
ACHN	NFvoNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV24O4xqOjVxNUCgcm0>	MYm0PEBp	MlSySG1UVw>?	M1jkbolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK=	MormNlUyPzZ\|NUS=
769-P	M{\BN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfqWI8zPS93MDDuUS=>	MUK0PEBp	NYjaVXgyTE2VTx?=	NGfBU\|dqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni	NIHQe3kzPTF5NkO1OC=>
Caki-1	MonMR49td267IF\vdo1ifGmxbjDBd5NigQ>?	NV7LSJg{PTBibl2=	MW[3MVE1KGR?	M3S2fGROW09?	MYTzeZBxemW\|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=>	MVyyOVE4PjN3NB?=
ACHN	NHHvbWVEd2yxbomgSo9zdWG2aX;uJGF{e2G7	NV\hSFh2PTBibl2=	NGPIcIo4NTF2IHS=	NXH5TJdnTE2VTx?=	NXnDWY96e3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB?	Mn7xNlUyPzZ\|NUS=
769-P	NFrseJZEd2yxbomgSo9zdWG2aX;uJGF{e2G7	NHHRXJU2OCCwTR?=	MV:3MVE1KGR?	M1SzXmROW09?	NIDH[2l{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>?	M2jkSlI2OTd4M{W0
Caki-1	M4HtfGFxd3C2b4Ppd{BCe3OjeR?=	M1jpZ\|UxKG6P	M2mzS\|Q5KGh?	NH[wZWNFVVOR	M3XKS4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	NFnYTXkzPTF5NkO1OC=>
ACHN	MVHBdI9xfG:\|aYOgRZN{[Xl?	M2nHZVUxKG6P	MmXqOFghcA>?	MoXYSG1UVw>?	NHXIc2tqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	NH25foczPTF5NkO1OC=>
769-P	M{XYWmFxd3C2b4Ppd{BCe3OjeR?=	MXK1NEBvVQ>?	MkexOFghcA>?	M1\VXmROW09?	MojLbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MlLwNlUyPzZ\|NUS=
MDA-MB-231	NFXlVYNOd3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl?	M1HQXVExyqCwTR?=	MoDQN:Kh\A>?	M2T6XGROW09?	MWfhcJRmenNiY3XscEBud3KyaH;sc4d6yqB?	MVWyOFgyODR7Nx?=
BT-549	NImzVJFOd3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl?	M{XP[lExyqCwTR?=	MVuzxsBl	MlLnSG1UVw>?	M2HGUYFtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?=	MXKyOFgyODR7Nx?=
MCF-7	NGXKVm1Od3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl?	NYrBUHVqOTEEoH7N	M3Tvb\|PDqGR?	NX3oV2Z[TE2VTx?=	NYrUWXpm[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg	NHXi[nEzPDhzMES5Oy=>
MCF-7	M3PyS2Z2dmO2aX;uJGF{e2G7	MUS1MVUxKG6P	MmnTNlQhcA>?	NWHReYJHTE2VTx?=	NGPQOXlz\WS3Y3XkJJRp\SCuZY\lcEBw\iCneIDy[ZN{cW:wIH;mJGVT\|rFuIGDSJIFv\CCIb4jBNeKh	MkHHNlQ{PjZ2MEe=
CTS	MorvRZBweHSxc3nzJGF{e2G7	MXyw5qCUPDBibl5CpC=>	MWW0PEBp		NV;O[VBFcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NVvj[ZV6OjR{NES0Nlk>
OCI-AML3	NHrJPJlCeG:ydH;zbZMhSXO\|YYm=	M1zub\|DjiJN2MDDuUeKh	Mn3oOFghcA>?		Mnf2bY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	Ml3lNlQzPDR2Mkm=
U937	MlPRRZBweHSxc3nzJGF{e2G7	NVfjUGxXOOLCk{SwJI5OyqB?	MVW0PEBp		NU\Eb2hFcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NIfWfJQzPDJ2NESyPS=>
PC3	M2jrTWFxd3C2b4Ppd{BCe3OjeR?=	NUTBT\|FNOC1zMECgcm0>	MWGyOE81QCCq		M2nMdolv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MV[yOFE3OzJ\|MB?=
PC3-AR	M2DYeWFxd3C2b4Ppd{BCe3OjeR?=	M2TmRVAuOTByIH7N	MWSyOE81QCCq		NHL3TlJqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NESwfG0zPDF4M{KzNC=>
PC3	M3\4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTlN3REOC1zMECgcm0>	M2DoUVI1NzR6IHi=		MofrbY5lfWOnczDhZ4N2dXWuYYTpc44hd2Zic4XiS\|EheG:ydXzheIlwdg>?	MonYNlQyPjN{M{C=
PC3-AR	NUK5bHNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHVPJZJOC1zMECgcm0>	M3ToflI1NzR6IHi=		M1vJUolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hfGinIFeyUUBxcGG\|ZR?=	MUSyOFE3OzJ\|MB?=
PC3	Mmq2SpVv[3Srb36gRZN{[Xl?	MmjyNE0yODBibl2=	NGiydZYzPCCq		MWLzeZBxemW\|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?=	MUGyOFE3OzJ\|MB?=
PC3-AR	M{jpWGZ2dmO2aX;uJGF{e2G7	MoPrNE0yODBibl2=	M2e2dlI1KGh?		NV;hS3Jqe3WycILld5NmeyCneIDy[ZN{cW:wIH;mJIFkfGm4YYTl[EBCXE1uIFHreEBidmRiRYLrNU8zKHC{b4TlbY4>	M325b\|I1OTZ\|MkOw
OS-RC-2	MnH6R4VtdCCYaXHibYxqfHliQYPzZZk>	M3rTfFAuOTByMDDuUS=>	Mn7kNlQwPDhxN{KgbC=>	M2XXb2ROW09?	MnXO[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NYf0e5U3OjRzNES3N\|c>
OS-RC-2	NFzKd2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXX5XFV2PTBibl2=	Mnn6OFghcA>?	MUXEUXNQ	MlPFbY5lfWOnczDHNk9OKGG{cnXzeC=>	Mk\0NlQyPDR5M{e=
OS-RC-2	M1HPRmFxd3C2b4Ppd{BCe3OjeR?=	M4LyZlUxKG6P	MmnxOFghcA>?	MWrEUXNQ	MWLpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NI\wVFIzPDF2NEezOy=>
SK-N-AS	NUXXfYlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;aNQKBmzhyIH7N	MnrjOFghcA>?		Mo\lTWM2OD1{Nz60JI5O	Mk\pNlQxQTh5OUm=
SK-N-DZ	Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXn1PVJVOOLCk{iwJI5O	M2XMXFQ5KGh?		M1mweGlEPTB;MkGuPUBvVQ>?	MX2yOFA6QDd7OR?=
SK-N-SH	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HFZVDjiJN6MDDuUS=>	MWi0PEBp		Mlz6TWM2OD15Mj6zJI5O	MnXCNlQxQTh5OUm=
SK-N-BE	M{DlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHSwRVMx6oDVOECgcm0>	NWLmUnN7PDhiaB?=		M374ZmlEPTB;N{WuOEBvVQ>?	Mn;uNlQxQTh5OUm=
SK-N-AS	MXzBdI9xfG:\|aYOgRZN{[Xl?	MWOw5qCUQDBibl2=	M1HxVlQ5KGh?		M3fWVZBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG\|aHnvci=>	NF\NcnkzPDB7OEe5PS=>
SK-N-DZ	NFTCUZZCeG:ydH;zbZMhSXO\|YYm=	MmL1NQKBmzhyIH7N	MY[0PEBp		NIr1RVJxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44>	NVH0TWdqOjRyOUi3PVk>
SK-N-SH	NXPXeppYSXCxcITvd4l{KEG\|c3H5	NV;h[pRrOOLCk{SwJI5O	MmewOFghcA>?		NGKwTZNxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44>	MYSyOFA6QDd7OR?=
SK-N-BE	NF7mOmFCeG:ydH;zbZMhSXO\|YYm=	NETweHox6oDVNECgcm0>	NU\0cWpSPDhiaB?=		MVHwc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36=	M3r3SlI1ODl6N{m5
SK-N-AS	MUXGeY5kfGmxbjDBd5NigQ>?	M{HtblDjiJN6MDDuUS=>	MkfEOFghcA>?		MWnpcoR2[2W\|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG\|ZTCzJIFv\CCSQWLQ	MV[yOFA6QDd7OR?=
SK-N-DZ	MVLGeY5kfGmxbjDBd5NigQ>?	MXyw5qCUQDBibl2=	NIPOepk1QCCq		NWDhNWF2cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>?	MlvENlQxQTh5OUm=
SK-N-SH	MYXGeY5kfGmxbjDBd5NigQ>?	MYmw5qCUPDBibl2=	NVLmb5ROPDhiaB?=		MlXCbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=>	MlHQNlQxQTh5OUm=
SK-N-BE	MW\GeY5kfGmxbjDBd5NigQ>?	M37H[FDjiJN2MDDuUS=>	NWrNRWl7PDhiaB?=		MkX0bY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=>	NHf0S\|kzPDB7OEe5PS=>
HCC-LM3	M2DRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVqxMVExODBibl2=	NFviV5czPC92OD:3NkBp	MlOzSG1UVw>?	NHLteVJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M3nCO\|I1ODl\|OUW2
HepG2	MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnZS2dVOS1zMECwJI5O	NYLrcHpsOjRxNEivO\|IhcA>?	NYLzOnhbTE2VTx?=	M4nIUIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M3\DTFI1ODl\|OUW2
SMMC-7721	NWexdYZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPaSZcyNTFyMECgcm0>	MWWyOE81QC95MjDo	M4jsdGROW09?	NGfoNIhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MYmyOFA6Ozl3Nh?=
HCC-LM3	MmTwRZBweHSxc3nzJGF{e2G7	NGfNcXM2OCCwTR?=	NXvMVpZOPDhiaB?=	Mne2SG1UVw>?	NI\yV2FqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[ZMhOyxiODDhcoQhQQ>?	MUKyOFA6Ozl3Nh?=
HepG2	NFnnZohCeG:ydH;zbZMhSXO\|YYm=	NX7oZnZ5PTBibl2=	NFrq[Ys1QCCq	NYTvfIZuTE2VTx?=	NGPqO2RqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[ZMhOyxiODDhcoQhQQ>?	MUGyOFA6Ozl3Nh?=
SMMC-7721	NUDwcYczSXCxcITvd4l{KEG\|c3H5	NY[xZZhjPTBibl2=	Mn7uOFghcA>?	MYfEUXNQ	MkXvbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC\|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk>	MkfINlQxQTN7NU[=
HCC-LM3	NYPKWVZiTnWwY4Tpc44hSXO\|YYm=	MmjMOVAwOTByIH7N	NFLTe2MzPCCq	NFfiTplFVVOR	M3LnfYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC=	NH;ObWszPDB7M{m1Oi=>
HepG2	NG\VNVNHfW6ldHnvckBCe3OjeR?=	M3\LOFUxNzFyMDDuUS=>	M3TTNlI1KGh?	NYfHfXBOTE2VTx?=	M3j5SoRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC=	NWi1bWg4OjRyOUO5OVY>
SMMC-7721	M3yzXmZ2dmO2aX;uJGF{e2G7	NF;WXHI2OC9zMECgcm0>	NELXXJIzPCCq	NF7lUHlFVVOR	MnPq[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?=	NVHYV5JUOjRyOUO5OVY>
HCC-LM3	NV;GWXlITnWwY4Tpc44hSXO\|YYm=	NFS0TmM2OC9zMECgcm0>	NUKzVI1ROjRiaB?=	NGO3SJpFVVOR	MU\kc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v	MnSzNlQxQTN7NU[=
HepG2	M2\UeGZ2dmO2aX;uJGF{e2G7	NXHzdI91PTBxMUCwJI5O	MYKyOEBp	M17NfWROW09?	MXTkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v	M2nZVVI1ODl\|OUW2
SMMC-7721	MY\GeY5kfGmxbjDBd5NigQ>?	MkX1OVAwOTByIH7N	NYrQXXBUOjRiaB?=	Mmq5SG1UVw>?	NXziOm9k\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?=	NVr0ZmhFOjRyOUO5OVY>
FaDu	MlS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XueVExOOLChX7N	NIP0R5g5NzFyL{GyJIg>		MlfC[Il{eGyjeXXkJIEhe2mpbnnmbYNidnRiYX7kJJBzd2yxbnfl[EBIOi:PIHHydoV{fCCjdDC4JIFv\CBzMvMAiYgheG:\|dDDy[Yxm[XOn	M4DyPVI1ODJ4NEiy
FaDu	M4PCcWZ2dmO2aX;uJGF{e2G7	NVfaZlFLOTBy4pEFcm0>	MofKNk81NzhxMUKgbC=>		MoCwbY5lfWOnZDDwNlFY[WZzL1PpdFHDqGW6cILld5Nqd25?	NHizbFQzPDB{NkS4Ni=>
PC-3	MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17XblAuOTBizszN	MWqyOE81QC95MjDo		NYHrN4p2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MWeyN\|k6OTJzNh?=
LNCaP	NGSybWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljDNE02KM7:TR?=	NYXpTINSOjRxNEivO\|IhcA>?		MoHwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NHvROG8zOzl7MUKxOi=>
RWPE-1	M17K[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rOclAuOjBizszN	MXqyOE81QC95MjDo		MXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MVKyN\|k6OTJzNh?=
Capan-1	NHHseHFHfW6ldHnvckBCe3OjeR?=	M3\0TlI2NzVyL{GwNEBvVQ>?	MUe4M\|I1NzR6IHi=	NFfqclZFVVOR	NFX1NXVld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n	MUWyN\|kzOjh6Nh?=
L3.6pl	MofkSpVv[3Srb36gRZN{[Xl?	MV:yOU82OC9zMECgcm0>	Ml:wPE8zPC92ODDo	NIC3N\|hFVVOR	M3fze4Rwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW\|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne=	NVXKTWdIOjN7MkK4PFY>
CFPAC-1	MmHrSpVv[3Srb36gRZN{[Xl?	M37h[\|I2NzVyL{GwNEBvVQ>?	MoLjPE8zPC92ODDo	MVrEUXNQ	Mn\p[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO\|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?=	M1zJdlI{QTJ{OEi2
Capan-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPNRnAzPS93MD:xNFAhdk1?	NXXqOFdrPDhiaB?=	NEj1dmJFVVOR	MlfudoVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MmPzNlM6OjJ6OE[=
L3.6pl	NY\ZPHNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTTVJVDOjVxNUCvNVAxKG6P	NUPnTWxSPDhiaB?=	NI\FWmpFVVOR	NEHZbYdz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M3HWO\|I{QTJ{OEi2
CFPAC-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;mdJRHOjVxNUCvNVAxKG6P	M1TOWVQ5KGh?	NWnYT4lyTE2VTx?=	Ml31doVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	M4D0NFI{QTJ{OEi2
Capan-1	NYjQcGFMSXCxcITvd4l{KEG\|c3H5	Ml\QNlUwPTBxMUCwJI5O	M2S1cFQ5KGh?	NHT2S5BFVVOR	MmTXbY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MX6yN\|kzOjh6Nh?=
L3.6pl	MnzmRZBweHSxc3nzJGF{e2G7	MUKyOU82OC9zMECgcm0>	M2LHPFQ5KGh?	NWWzUng2TE2VTx?=	MYPpcoR2[2W\|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MXWyN\|kzOjh6Nh?=
CFPAC-1	MWrBdI9xfG:\|aYOgRZN{[Xl?	M{nNWFI2NzVyL{GwNEBvVQ>?	M2m4clQ5KGh?	Mo\hSG1UVw>?	NVq0RYhtcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M37ib\|I{QTJ{OEi2
HN22	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHQNE0zOCCwTR?=	MVuyOE81QCCq	M3jPRWROW09?	NYXveZVYcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>?	NYf5dY81OjN6N{eyN\|U>
HSC4	NWnvPI1sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3[2ZVAuOjBibl2=	MnKxNlQwPDhiaB?=	M{jybGROW09?	M{XNcolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI>	NGDWS4ozOzh5N{KzOS=>
HN22	MnrGRZBweHSxc3nzJGF{e2G7	M1vVWVAuOjBibl2=	NYXEVGNtPDhiaB?=	MonCSG1UVw>?	Mln0bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MVSyN\|g4PzJ\|NR?=
HSC4	NWDDR4tjSXCxcITvd4l{KEG\|c3H5	MYGwMVIxKG6P	NEjmWno1QCCq	NGDCSGZFVVOR	NUm0bpo{cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	M3rYTlI{QDd5MkO1
HN22	M3;Bbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{Lmd\|AuOjBibl2=	M37KU\|Q5KGh?	MX\EUXNQ	MofybY5lfWOnczDHNUBxcGG\|ZTDj[YxtKGO7Y3zlJIFzemW\|dNMg	MUGyN\|g4PzJ\|NR?=
HSC4	NGOxdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX2yUJRnOC1{MDDuUS=>	MoTLOFghcA>?	MX7EUXNQ	MmG1bY5lfWOnczDHNUBxcGG\|ZTDj[YxtKGO7Y3zlJIFzemW\|dNMg	Mo\LNlM5Pzd{M{W=
HN22	NFHpXXRHfW6ldHnvckBCe3OjeR?=	NH;LNpcxNTJyIH7N	MVy0PEBp	Mmi5SG1UVw>?	MmG3d5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg	NFrDWXkzOzh5N{KzOS=>
HSC4	MXvGeY5kfGmxbjDBd5NigQ>?	M2HZe\|AuOjBibl2=	MVm0PEBp	NW[5ZWdtTE2VTx?=	Mnq5d5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg	NWfseWl{OjN6N{eyN\|U>
Cal62	NYXsfGN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTN\|INMxJFQhdk1?	M{O1[FI{QDJ2ME[0
Hth7	M175RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3ThTWlEPTB;MUWgxtEhOiCwTR?=	MnHWNlM5OjRyNkS=
Hth83	NIftSItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTN2INMxJFUhdk1?	MUSyN\|gzPDB4NB?=
C643	MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPlbZBzUUN3ME23NUDDuSBzMDDuUS=>	M{PDOlI{QDJ2ME[0
SW1736	MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTnb\|NrUUN3ME2zOUDDuSB6IH7N	M{TBfVI{QDJ2ME[0
T241	NVr3Z4d6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfNVVdKSzVyPU[1JOKyKDdibl2=	MmLDNlM5OjRyNkS=
T351	NU\YTFVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnITWM2OD13MDFCtUAyOCCwTR?=	NIPYeHUzOzh{NEC2OC=>
BHP2-7	M4nsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vzfmlEPTB;M{egxtEhPiCwTR?=	NFPIPXAzOzh{NEC2OC=>
T238	NYrJN5BzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;3dXNKSzVyPUGsOVAxKMLzIEKwNEBvVQ>?	Ml;MNlM5OjRyNkS=
HCT8	NWf5VZJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYGy[4RNPzJiaB?=	NXThUoROTE2VTx?=	NEXQVXlKSzVyPUGyMlnjiIoEsfMAjVEvQSCwTR?=	MnfINlMzQTl\|OEi=
H630	M4C5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV63NkBp	M2\rb2ROW09?	M2PhR2lEPTB;MUKuOQKBkcLz4pEJN{4yKG6P	NFHJUXozOzJ7OUO4PC=>
cH630 5-FU-res	M1e1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2LsN\|czKGh?	MlWxSG1UVw>?	M1zPSGlEPTB;MUWuOgKBkcLz4pEJNU4zKG6P	NX\MU3JQOjN{OUmzPFg>
HCT116	MlnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYfKeZB2PzJiaB?=	NVvvNXZUTE2VTx?=	MXTJR\|UxRTFyLkhihKnDueLCiUKuNkBvVQ>?	MVqyN\|I6QTN6OB?=
HCT116 p53−/−	M{TPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFHq[YU4OiCq	MmfDSG1UVw>?	NVHsTnZTUUN3ME24MlbjiIoEsfMAjVEvPyCwTR?=	MnvSNlMzQTl\|OEi=
dHCT116 p21−/−	NHT5WWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoTaO\|IhcA>?	MkT2SG1UVw>?	MYrJR\|UxRTVwOfMAjeKy6oDLMT6zJI5O	NFLWbJAzOzJ7OUO4PC=>
HT29	NWLXSIRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWXDcJJ6PzJiaB?=	NXfC[2h5TE2VTx?=	MW\JR\|UxRTF4LkRihKnDueLCiUKuN{BvVQ>?	NFi3Oo0zOzJ7OUO4PC=>
LoVo	NXziSIxHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NE\Qe5A4OiCq	NXi0fGFuTE2VTx?=	NXX1ZWxGUUN3ME21MlHjiIoEsfMAjVAvPiCwTR?=	MWiyN\|I6QTN6OB?=
RKO	NVPJPZVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYC3NkBp	NYH4SY9QTE2VTx?=	NIixS5ZKSzVyPUeuPgKBkcLz4pEJNk4zKG6P	NH3ndHIzOzJ7OUO4PC=>
SW480	NXrRT5h3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NX7MfXZCPzJiaB?=	Mne1SG1UVw>?	MVjJR\|UxRTF5LkZihKnDueLCiUCuPEBvVQ>?	M3ztfFI{Ojl7M{i4
eSW620	M17FdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkPqO\|IhcA>?	Mlq5SG1UVw>?	NH\YbHhKSzVyPUmuNgKBkcLz4pEJNk4yKG6P	MWSyN\|I6QTN6OB?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DNMT1 / EZH2; PubMed: 19279403 Cancer Biol Ther Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control. caspase-8 / cleaved caspase-8 / Sp1; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. c-Myc / IRF4; PubMed: 27738323 Oncotarget RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting. Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; PubMed: 28915627 Oncotarget Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1. RAD51 / BRCA1 / CHK1 / RPL13a; PubMed: 24244429 PLoS One CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells. H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; PubMed: 31071955 Int J Mol Sci Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.	19279403 27738323 28915627 24244429 31071955
Immunofluorescence	Synaptophysin / NACM; PubMed: 28915627 Oncotarget Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm. α-tubulin / Acetyl-α-tubulin; PubMed: 29983882 Oncotarget CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm. BiP; PubMed: 23544167 Transl Oncol Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. ATF4; PubMed: 23544167 Transl Oncol HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. IRE1α / S724-IRE1α; PubMed: 23544167 Transl Oncol Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.	28915627 29983882 23544167
Growth inhibition assay	Cell viability; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.	27738323

体内研究

LBH589作用于患肺癌和间皮瘤动物模型,明显降低肿瘤生长，与对照组相比平均降低62%。LBH589作用于免疫活性鼠和严重联合免疫缺陷鼠效果差不多，说明LBH589抑制肿瘤生长与免疫学无关。LBH589按20 mg/kg剂量腹腔注射，每周持续5天，导致在实验最后肿瘤生长平均下降70%。与相应的对照组肿瘤相比，LBH589作用于H526衍生的肿瘤下降53%，作用于BK-T衍生的肿瘤下降81%, 作用于RG-1衍生的肿瘤下降76%，作用于H69衍生的肿瘤下降 70%。在相同条件和剂量的情况下，LBH589 作用于NSCLC和Meso衍生的移植瘤，导致SCLC衍生的肿瘤中有两种衰退，伴随着BK-T衍生的平均肿瘤尺寸从实验开始时的296 mm³降低到实验结束时的116 mm³，RG-1衍生的平均肿瘤尺寸从实验开始时的185mm³降低到实验结束时的86 mm³。^[2]

细胞实验：^[1]	- 合并 Cell lines: MOLT-4细胞和Reh(前体B细胞) Concentrations: 50 nM Incubation Time: 48小时 Method: 没有处理的细胞和LBH589处理的细胞[人类急性成淋巴细胞性白血病MOLT-4(T 细胞)和Reh(前体-B细胞)]用膜联蛋白V和碘化丙啶染色，然后加入膜联蛋白V-FITC细胞凋亡检测试剂盒I。通过流式细胞仪测定细胞凋亡和不能存活细胞的百分比。用CyAn ADP Violet细胞计数器收集至少5×10⁴个细胞。根据所有的膜联蛋白V-阳性和膜联蛋白V/PI-阳性细胞细胞计算凋亡百分比，根据所有的膜联蛋白V-阳性和PI-阳性及膜联蛋白V/PI-阳性细胞计算细胞活力丢失百分比。 (Only for Reference)
动物实验：^[2]	- 合并 Animal Models: 携带10×10⁶个M30细胞或5×10⁶个A549细胞的SCID鼠 Formulation: 溶于水的5%葡萄糖 Dosages: 10 mg/kg, 20 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	69 mg/mL (197.46 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+48% PEG 300+2% Tween 80+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Panobinostat (LBH589) SDF

分子量	349.43
化学式	C₂₁H₂₃N₃O₂
CAS号	404950-80-7
储存条件	3年 -20°C粉状
储存条件	2年 -80°C 溶于溶剂
别名	NVP-LBH589

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03632317	Withdrawn	Drug: Panobinostat\|Drug: Everolimus	Glioma\|Diffuse Intrinsic Pontine Glioma	University of Michigan Rogel Cancer Center	October 2019	Phase 2
NCT03982134	Withdrawn	Drug: PDR001\|Drug: Panobinostat	Melanoma\|Non Small Cell Lung Cancer	Muhammad Furqan\|Novartis Pharmaceuticals\|University of Iowa	September 2019	Phase 1
NCT03515915	Recruiting	--	Patients With Recurrent or Refractory Multiple Myeloma	University Hospital Montpellier\|Poitiers University Hospital	April 23 2018	--

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
How to reconstitute the compound for in vivo mice study?
回答：
We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

选择性强的HDAC抑制剂

RGFP966 : HDAC3-selective, IC50=80 nM.
选择性强的HDAC抑制剂

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
活性最高的HDAC抑制剂

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA批准的HDAC抑制剂

Vorinostat (SAHA, MK0683) : Approved by FDA for cutaneous T cell lymphoma.
最新的HDAC抑制剂

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

研究领域

产品类型

Panobinostat (LBH589)

客户使用Selleck该产品发表文献216篇：

产品安全说明书

HDAC抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Panobinostat (LBH589) SDF

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

技术支持

常见问题及建议解决方法

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品